North European Oil Royalty Trust press release (NRT): Q3 Net income of $4.29M.Total royalty income of $ of $4.45M (+200.7% Y/Y).
→ Google ترجمة
North European Oil Royalty Trust declares $0.46 dividend
→ Google ترجمة
Gainers AMTD Digital Inc. (NYSE: HKD ) climbed 71.5% to close at $27.80 on Monday after gaining 108% on Friday. The company priced its IPO at $7 per share. SKYX Platforms Corp. (NASDAQ: SKYX ) jumped 43.2% to close at $4.91. Qudian Inc. (NYSE: QD ) gained 40.3% to close at $1.67 after the company highlighted progress in its QD Food brand and said its 717 Foodies Festival fueled sales of approximately 9.56 million dishes. Intelligent Living Application Group Inc. (NASDAQ: ILAG ) shares gained 37.8% to close at $3.10 on Monday after declining 11% on Friday. The company reported closing of $20.24 million initial public offering. Exela Technologies, Inc. (NASDAQ: XELA ) rose 34.3% to close at $0.1350. Troika Media Group, Inc. (NASDAQ: TRKA ) gained 31.5% to close at $0.8040. Tantech Holdings Ltd (NASDAQ: TANH ) jumped 23.1% to close at $0.32 after the company posted a narrower FY loss. Avenue Therapeutics, Inc. (NASDAQ: ATXI ) shares gained 22.7% to settle at $0.3220. EZFill Holdings Inc.
→ Google ترجمة
Gainers: Advent Technologies Holdings (ADN) +24%. North European Oil Royalty Trust (NRT) +20%. Losers: Energy Vault Holdings (NRGV) -7%.
→ Google ترجمة
Gainers: Qudian QD +48%.Marathon Digital MARA +32%.SQL Technologies SKYX +27%.SOS (SOS) +25%.Hut 8 Mining HUT +24%.North European Oil Royalty Trust (NRT) +24%.Advent…
→ Google ترجمة
U.S. stocks traded higher midway through trading, with the Nasdaq Composite gaining more than 1% on Monday. The Dow traded up 0.55% to 31,460.80 while the NASDAQ rose 1.15% to 11,584.68. The S&P also rose, gaining, 0.7709% to 3,890.32. Also check this: Costco Wholesale And 3 Other Stocks Insiders Are Selling Leading and Lagging Sectors Energy shares rose 2.8% on Monday. Meanwhile, top gainers in the sector included North European Oil Royalty Trust (NYSE: NRT ), up 20% and BP Prudhoe Bay Royalty Trust (NYSE: BPT ) up 14%. In trading on Monday, utilities shares fell by 0.7%. Top Headline The NAHB housing market index fell to 55 in July, recording the weakest reading since May 2020, down from June’s reading of 67. Analysts, however, were expecting a reading of 65. Equities Trading UP Tantech Holdings Ltd (NASDAQ: TANH ) shares shot up 63% to $0.4228 after the company posted a narrower FY loss. Shares of Qudian Inc. (NYSE: QD ) got a boost, shooting 52% to $1.8050 after the company … Full story available on Benzinga.
→ Google ترجمة
Gainers Intelligent Living Application Group Inc. (NASDAQ: ILAG ) shares jumped 90.2% to $4.2792 after declining 11% on Friday. The company reported closing of $20.24 million initial public offering. Qudian Inc. (NYSE: QD ) rose 76.4% to $2.0991 after the company highlighted progress in its QD Food brand and said its 717 Foodies Festival fueled sales of approximately 9.56 million dishes. Tantech Holdings Ltd (NASDAQ: TANH ) gained 57.9% to $0.4104 after the company posted a narrower FY loss. AMTD Digital Inc. (NYSE: HKD ) jumped 49.2% to $24.18 after gaining 108% on Friday. The company priced its IPO at $7 per share. Advent Technologies Holdings, Inc. (NASDAQ: ADN ) shares gained 27% to $3.34 after the company''s Green HiPo project received official ratification from the European Commission. Marathon Digital Holdings, Inc. (NASDAQ: MARA ) surged 19.7% to $9.63 in sympathy with the price of Bitcoin. SKYX Platforms Corp. (NASDAQ: SKYX ) gained 18.6% to $4.07. IO Biotech, Inc. (NASDAQ: IOBT ) surged 18.4% to $5.04.
→ Google ترجمة
In trading on Monday, rental, leasing, & royalty shares were relative leaders, up on the day by about 6.4%. Leading the group were shares of North European Oil Royality Trust, up about 22.7% and shares of BP Prudhoe Bay Royalty Trust up about 15.1% on the day.
→ Google ترجمة
North European Oil Royalty Trust owns royalties on a large natural gas field in Germany. NRT is the perfect vehicle to gain exposure to the European natural gas price.
→ Google ترجمة
U.S. stocks pared gains midway through trading, with the Nasdaq Composite and S&P 500 turning lower on Tuesday. The Dow traded up 0.16% to 31,490.02 while the NASDAQ fell 0.72% to 11,441.85. The S&P also fell, dropping, 0.12% to 3,895.32. Also check this: U.S. Consumer Confidence And Other Macro Issues For Tuesday Leading and Lagging Sectors Energy shares jumped by 2.9% on Tuesday. Meanwhile, top gainers in the sector included Earthstone Energy, Inc. (NYSE: ESTE ), up 9% and North European Oil Royalty Trust (NYSE: NRT ) up 7%. In trading on Tuesday, consumer discretionary shares fell by 0.9%. Top Headline U.S. goods gap shrank to $104.3 billion in May versus a revised $106.7 billion in April, recording the lowest trade gap so far this year. Exports rose 1.2% to a record high, with imports declining 0.1%. Equities Trading UP Kezar Life Sciences, Inc. (NASDAQ: KZR ) shares shot up 72% to $9.92 after the company announced topline results from the MISSION Phase 2 clinical trial evaluating zetomipzomib.
→ Google ترجمة
North European Oil Royalty is a good hedge against inflation. Read more to see why investors interested in exposure to potential inflation-beating prospects should look at NRT.
→ Google ترجمة
U.S. stocks remained lower midway through trading on Tuesday, amid the ongoing Russia-Ukraine conflict. The Dow traded down 1.17% to 33,497.30 while the NASDAQ fell 0.40% to 13,696.04. The S&P also fell, dropping, 0.74% to 4,341.75. Check out this: Insiders Buy Around $98M Of 3 Stocks Leading and Lagging Sectors Energy shares climbed by 0.9% on Tuesday. Meanwhile, top gainers in the sector included New Fortress Energy Inc. (NYSE: NFE ), up 14% and North European Oil Royalty Trust (NYSE: NRT ) up 10%. In trading on Tuesday, energy shares fell by 2.8%. Top Headline Target Corporation (NYSE: TGT ) reported better-than-expected earnings for its fourth quarter, while sales missed estimates. Target posted quarterly earnings of $3.19 per share, beating analysts’ estimates of $2.86 per share. The company’s quarterly sales came in at 31.00 billion, missing expectations of $31.41 billion. Target said it sees low-to-mid single digit revenue growth for 2022. Equities Trading UP iQIYI, Inc. (NASDAQ: IQ ) shares shot up 30% to $5.39 after the company reported fourth-quarter FY21 revenue of $1.2 billion, flat year-on-year, beating the consensus of $1.15 billion.
→ Google ترجمة
SYDNEY , June 30, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to provide an update on recent progress with its two pipeline assets, paxalisib and EVT801. Key Points GBM AGILE pivotal study of paxalisib is recruiting ahead of expectations, with almost 25 sites now open to the paxalisib arm. Paxalisib phase II study in newly diagnosed glioblastoma has seen the final patient complete drug treatment; a number of patients remain in follow-up. EVT801 phase I study protocol has been submitted to the French regulatory agency for review. Kazia CEO, Dr James Garner , commented, "Kazia has seen an exceptionally busy first half, with excellent progress across our clinical programs. In particular, the GBM AGILE study is performing ahead of our forecasts in terms of recruitment. As we move into the second half of the year, we anticipate conclusion of the paxalisib phase II study, initial data readouts from a number of the paxalisib investigator-initiated studies in other forms of brain cancer, and commencement of the first-in-human phase I study of EVT801." GBM AGILE Almost twenty-five sites are currently open to the paxalisib arm in the United States .
→ Google ترجمة
SYDNEY, June 15, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that it has entered a collaboration with the Joan & Sanford I Weill Medical College of Cornell University in the United States,
→ Google ترجمة
Kazia''s investigational drug, Paxalisib, is set to be involved in its ninth ongoing clinical study. The post Heres why the Kazia Therapeutics (ASX:KZA) share price got a 6% boost today appeared first on The Motley Fool Australia .
→ Google ترجمة
Sydney, June 07, 2021 (GLOBE NEWSWIRE) -- Proactive, provider of real-time news and video interviews on growth companies listed in Australia, has covered the following companies:
→ Google ترجمة
The global effort to defeat cancer continues, with this ASX healthcare share commencing a new clinical study. The post Up 220% in 1-year, Kazia Therapeutics (ASX:KZA) share price is edging lower today appeared first on The Motley Fool Australia .
→ Google ترجمة
Kazia Therapeutics Ltds (ASX:KZA) (FRA:NV9M) (NASDAQ:KZIA) phase-II study of paxalisib in Primary CNS Lymphoma has been initiated at Dana-Farber Cancer Institute in Boston, Massachusetts, with the first patient enrolled to the study. Lymphoma is a cancer of white blood cells that occurs in the lymphatic system and can spread almost anywhere in the body while primary CNS lymphoma (PCNSL) occurs exclusively in the brain and central nervous system. The PI3K inhibitor class, to which paxalisib belongs, is well validated in lymphoma outside the brain; three of the four FDA-approved PI3K inhibitors are treatments for forms of lymphoma, but they are assumed ineffective for PCNSL since they cannot cross the blood-brain barrier. Leading cancer centre Dana-Farber Cancer Institute (DFCI) is a world-leading cancer treatment and research centre with its principal teaching affiliate being Harvard National Medical School. DFCI participates in as many as 600 clinical trials at any given time and has been an important contributor to the development of many important new cancer therapies. "Very sound rationale" Chief executive officer Dr James Garner said: We are delighted to see this study underway and congratulate Dr Nayak and her team on getting it launched. With paxalisib now in an international pivotal study for glioblastoma, we are increasingly focused on identifying other groups of patients who may benefit from the drug. There is a very sound rationale to explore PCNSL in this disease and we are looking forward to seeing the study progress. Strong research focus The DFCI study (NCT04906096) is an open-label phase II clinical trial of paxalisib in PCNSL, and is expected to recruit up to 25 patients, taking up to two years to complete.
→ Google ترجمة
Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that a phase II study of Kazia''s investigational new drug, paxalisib, in primary CNS lymphoma has been initiated at Dana-Farber Cancer Institute.
→ Google ترجمة
Kazia Therapeutics Limited (NASDAQ: KZIA), an oncology-focused drug development company, announced today that its CEO, Dr James Garner , will be presenting virtually at the upcoming LD Micro Invitational XI.
→ Google ترجمة
Kazia Therapeutics Ltd (ASX:KZA) (NASDAQ:KZIA) (FRA:NV9M) directors have demonstrated confidence in the companys bio-tech strategy with on-market share purchases. Non-executive director Steven Coffey acquired 8,000 shares in an indirect interest on June 1 and 2, increasing his holding to 426,250 shares with another 8,015 held in a direct interest. On May 31 executive director and CEO Dr James Garner purchased 10,000 shares in a direct interest, increasing the number of securities held to 430,000. Non-executive director Bryce Carmine acquired 20,000 shares on May 31 in a direct interest, increasing his holding to 372,692 shares. This follows multiple purchases made by KZA directors on May 3. March quarter highlights The company kicked off 2021 with a trifecta of March quarter licensing deals, leaving it "a vastly stronger and more substantial business", according to CEO Dr James Garner. During the quarter, the oncology-focused drug development company saw maiden revenue of A$5.3 million and its cash position increased to A$19.7 million by the end of March.
→ Google ترجمة
North European Oil Royalty Trust (NYSE:NRT) declared a quarterly dividend on Monday, May 3rd, Wall Street Journal reports. Shareholders of record on Friday, May 14th will be given a dividend of 0.14 per share by the energy company on Wednesday, May 26th. This represents a $0.56 annualized dividend and a dividend yield of 9.02%. The []
→ Google ترجمة
Kazia Therapeutics announce their quarterly, annual earnings. See the latest EPS estimates. Listen to the conference call and remind yourself by…
→ Google ترجمة
09 Dec 2020 - Kazia Therapeutics (ASX:KZA) released data from their phase 1 study of Cantrixil in patients with ovarian cancer.
→ Google ترجمة